English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Because of the higher risk of drug use, especially benzodiazepines, treating sleep disorders in patients, undergoing Methadone Maintenance Therapy, is one of the daily challenges of addiction therapists. Pregabalin is an antiepileptic drug that is used for insomnia and neuropathic pain. It seems that pregabalin has a lower risk of dependency than benzodiazepines. A total of 107 patients  participated in this study . Participants randomly assigned to intervention and control groups. The intervention group received 75 mg of pregabalin and the control group received placebo over 8 weeks. The main instruments of the study were the Pittsburgh Sleep Quality Index (PSQI) and Demographic Questionnaire to collect data on the sleep quality of the MMT patients. Sleep duration and sleep efficiency significantly improved in the pregabalin group compared to the placebo group but in other scales of sleep quality, no significant difference is found between the two groups. The current study used a low dose of pregabalin for treating sleep disturbances in patients being treated with methadone, however; it is suggested that future studies may use higher doses of pregabalin (e.g., 150 and 300 mg) for enhancing the different components of sleep quality as well as overall sleep quality.

The effect of Pregabalin on sleep quality of patients treated with methadone maintenance therapy: A double-blind randomized clinical trial